Drugging the Undruggable: New Acquisition to Boost GPCR Drugs
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its…
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its…
Biotech is one of the main forces driving the development of effective therapies to treat neurological and…
Researchers from King’s College London have succeeded in developing a blood test that can help choose…
I mean, Clinical depression is a tough indication for Biotech to tackle - particularly when facing…
Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is…
Mini brains, about 3-4 mm are a breakthrough in Neurology which will enable researchers to…
Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment…
Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces…
AOP Orphan Pharmaceuticals and Confluence Pharmaceuticals, signed today a definitive agreement to co-develop and market…
Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and…